In recent years, more and more Chinese biotech startups were founded and under rapid development. Chinese industries of innovative drug development was stared with ‘Me too’, and increasingly moved forward to ‘First in Class’. Nevertheless, establishment model of biotech startups is relatively simple, most of which were founded by some of members from management team or directors from big pharmaceutical companies, and then got investment from venture capitals focusing on one to two therapeutic areas or technology platforms. Over the past five years, however, Hub-and-Spoke model began to emerge for biotech, which got a lot of money from venture capitals in America and Europe. Instead of focusing on a single technology or in the traditional way, Hub-and-Spoke model biotech covers different therapeutic areas, indications, and technologies, while have only one management team. This article puts forward the definition, strength, weakness and current development status of Hub-and-Spoke model in biotech startups, and meanwhile, clarifies the application of this model in biotech by case studies, hoping for providing reference in the establishment of Chinese biotech startups.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |